Key Highlights

  • AstraZeneca PLC (LSE:AZN) is trending on 9 November 2026 as the FTSE 100 rose 1.02% to 10,782.87 and pharma stocks were compared with cyclicals.
  • Nine-month total Revenue rose 7% at constant currency to $46.9 billion, with core Earnings Per Share up 14% to $8.00.
  • Third-quarter revenue was $16.2 billion and core EPS rose 17%, while 12 positive Phase III programme readouts were reported in the year to date.
  • 2026 guidance was reiterated: mid-to-high single-digit revenue growth and low double-digit core EPS growth.

Why AstraZeneca PLC (LSE:AZN) Is in Focus Today

AstraZeneca PLC (LSE:AZN) is trending on 9 November 2026 as investors compare the UK’s largest listed company with other defensive names after a day of cyclical buying. The FTSE 100 closed 1.02% higher at 10,782.87, while Haleon, Smith & Nephew and GSK lagged. AstraZeneca stands out because of its nine-month results on 30 October, when the shares rose about 3% to around 13,446p after another earnings beat, and because its pipeline continues to deliver positive news.

With a Market Value that dominates the FTSE 100, moves in the stock have an outsized effect on the index.

Nine-Month and Third-Quarter Results

Total revenue for the nine months to 30 September rose 7% at constant currency to $46.88 billion, with product sales of $43.96 billion and alliance revenue up 33%. Core operating profit and core EPS both grew 14%, with core EPS at $8.00 and reported EPS at $5.62. In the third quarter, revenue was $16.21 billion, up 7%, and core EPS rose 17% to $2.79. Oncology grew 16% and made up 47% of revenue, Respiratory and Immunology rose 10% and Rare Disease grew 11%, offsetting declines in cardiovascular and metabolic medicines hit by loss of exclusivity on Farxiga and Brilinta.

Pipeline Momentum

The company reported 12 positive Phase III programme readouts in the year to date and 47 approvals in major regions since its previous results, including first approvals for four new medicines. Three new molecular entities delivered first Phase III data, and management said its upcoming readouts in 2027 have a potential peak-year revenue of more than $20 billion. AstraZeneca aims to deliver 20 new molecular entities by 2030, with 14 achieved so far, and it remains on track for its 2030 revenue ambition.

Guidance and Cash

The company reiterated 2026 guidance for mid-to-high single-digit total revenue growth and low double-digit core EPS growth at constant currency, with a core tax rate of 18% to 22%. Operating Cash Flow was lower because of Working Capital movements linked to the US loss of exclusivity for Farxiga, higher tax payments and currency effects. For holders of LSE:AZN, cash conversion and Dividend growth remain important.

Risks Investors Are Weighing

Patent expiries, US drug pricing policy and tariffs, volume-based procurement in China, clinical trial setbacks and the cost of acquisitions are the main risks. Currency moves affect reported revenue and the shares are sensitive to pipeline news.

Therapy Areas and Commercial Strategy

Oncology is the largest therapy area, with medicines such as Enhertu, Imfinzi, Tagrisso and Datroway driving growth and many new indications in late-stage development. Respiratory and Immunology provides steady growth from Breztri, Fasenra and Tezspire, while Rare Disease, led by the Alexion portfolio, has delivered double-digit growth. The company’s presence in emerging markets, including China, adds both opportunity and risk because volume-based procurement can reduce prices.

Management has also invested in new platforms such as cell therapy, radioconjugates and AI-enabled discovery, which it believes will support growth into the next decade. Those programmes require significant research spending, and investors judge returns by the number and quality of positive readouts.

Sector Context

AstraZeneca’s rise of about 3% on its results day contrasted with GSK’s fall on 28 October, showing how stock-specific delivery drives performance. On 9 November the pharma group lagged the cyclical rally along with Haleon and Smith & Nephew, but its earnings momentum remains a differentiator for LSE:AZN.

What Investors Are Watching Next

Investors will follow regulatory decisions on new medicines, further Phase III results, US pricing developments and the full-year results, which will update 2027 expectations. Updates from other large pharma groups and any policy announcements on drug pricing will also influence sentiment.

Valuation and Key Takeaways

AstraZeneca trades at a premium to many large pharma peers because of its growth and pipeline depth. That premium means investors expect consistent delivery, and any setback could cause a sharp reaction. For the long term, the combination of oncology Leadership and new launches supports the case, while currency and policy risks need monitoring.

Outlook

AstraZeneca PLC (LSE:AZN) continues to deliver double-digit earnings growth and a rich pipeline. Rotation toward cyclicals may weigh on defensive names in the short term, but the fundamentals remain firm.